A Phase 1 Open-label Pharmacokinetics Study Of Palbociclib, A Cyclin-dependent Kinase 4 And 6 (cdk4/6) Inhibitor, In Postmenopausal Chinese Women With Er (+), Her2 (-) Advanced Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Palbociclib (Primary)
- Indications Adenocarcinoma; Breast cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 11 Apr 2017 Status changed from suspended to active, no longer recruiting.
- 16 Mar 2017 Status changed from active, no longer recruiting to suspended.